FibroGen Inc (NASDAQ:FGEN) CEO Sells $1,751,911.20 in Stock

FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 39,636 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $44.20, for a total value of $1,751,911.20. Following the transaction, the chief executive officer now owns 2,449,106 shares of the company’s stock, valued at $108,250,485.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of NASDAQ FGEN opened at $44.31 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.16 and a quick ratio of 6.16. The firm has a market capitalization of $3.82 billion, a P/E ratio of -43.02 and a beta of 1.75. FibroGen Inc has a one year low of $33.51 and a one year high of $68.55.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.15. The business had revenue of $23.90 million during the quarter, compared to analyst estimates of $20.44 million. FibroGen had a negative return on equity of 17.71% and a negative net margin of 44.14%. FibroGen’s revenue was down 25.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.50) earnings per share. Equities analysts anticipate that FibroGen Inc will post -0.87 EPS for the current year.

A number of research analysts have recently commented on FGEN shares. Piper Jaffray Companies reiterated a “positive” rating and set a $40.00 price target (down from $65.00) on shares of FibroGen in a report on Monday, May 27th. BidaskClub lowered FibroGen from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. William Blair lowered FibroGen from an “outperform” rating to a “market perform” rating in a report on Friday, May 10th. Mizuho cut their price target on FibroGen from $74.00 to $65.00 and set a “positive” rating for the company in a report on Friday, May 10th. Finally, Goldman Sachs Group reiterated a “neutral” rating and set a $45.00 price target on shares of FibroGen in a report on Wednesday, May 29th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. FibroGen has an average rating of “Buy” and a consensus price target of $61.57.

Several hedge funds and other institutional investors have recently modified their holdings of FGEN. Vanguard Group Inc raised its stake in shares of FibroGen by 1.8% in the third quarter. Vanguard Group Inc now owns 6,921,874 shares of the biopharmaceutical company’s stock valued at $420,503,000 after purchasing an additional 125,186 shares in the last quarter. Bank of Montreal Can raised its stake in shares of FibroGen by 177.3% in the fourth quarter. Bank of Montreal Can now owns 1,722 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 1,101 shares in the last quarter. Rhumbline Advisers raised its stake in shares of FibroGen by 55.4% in the fourth quarter. Rhumbline Advisers now owns 111,700 shares of the biopharmaceutical company’s stock valued at $5,169,000 after purchasing an additional 39,812 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of FibroGen in the fourth quarter valued at $281,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of FibroGen in the fourth quarter valued at $2,133,000. Institutional investors and hedge funds own 66.27% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Featured Article: What is the Federal Reserve?

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.